手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| Caco-2細胞透過性アッセイ× | 集団薬物動態モデル（Population Pharmacodynamic Modeling）× | |
|---|---|---|
| 分野 | 薬理学 | 薬理学 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 1989 | 1992 |
| 提唱者≠ | Ingrid Hidalgo | Lewis Sheiner and Stephen Roush |
| 種類≠ | absorption screening | dose-response modeling |
| 原典≠ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ | Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57. link ↗ |
| 別名 | Caco-2 assay, intestinal permeability, ADME screening | PopPD, population PD, hierarchical PD modeling |
| 関連 | 3 | 3 |
| 概要≠ | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. | Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction. |
| ScholarGateデータセット ↗ |
|
|